Exeter Financial LLC Has $226,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Exeter Financial LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 14.7% during the 1st quarter, Holdings Channel.com reports. The fund owned 4,396 shares of the biopharmaceutical company’s stock after selling 758 shares during the quarter. Exeter Financial LLC’s holdings in Bristol-Myers Squibb were worth $226,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. lifted its position in Bristol-Myers Squibb by 532.7% in the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,582 shares in the last quarter. Institute for Wealth Management LLC. lifted its position in shares of Bristol-Myers Squibb by 1.0% during the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock worth $1,542,000 after buying an additional 296 shares in the last quarter. Great Diamond Partners LLC lifted its position in shares of Bristol-Myers Squibb by 9.2% during the 4th quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 367 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $5,161,000. Finally, Principal Securities Inc. bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $1,139,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded down $0.70 during midday trading on Thursday, reaching $41.80. 7,058,896 shares of the company traded hands, compared to its average volume of 15,638,709. The firm has a market capitalization of $84.73 billion, a price-to-earnings ratio of -13.56, a price-to-earnings-growth ratio of 14.28 and a beta of 0.43. The business has a 50 day moving average of $43.25 and a two-hundred day moving average of $48.27. Bristol-Myers Squibb has a 12 month low of $39.63 and a 12 month high of $65.38. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period last year, the firm earned $2.05 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.74%. Bristol-Myers Squibb’s payout ratio is presently -77.42%.

Analysts Set New Price Targets

Several equities analysts have commented on BMY shares. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Barclays reduced their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.